Tested inhaler for children with asthma ages 6–11
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be 6 to under 12 years old at the start of the random study treatment
- Your child must have a confirmed asthma diagnosis for at least 12 months
- Your asthma must be symptomatic at the randomization visit (symptom score ACQ-IA must be at least 1.5)
- Before starting, your child must be on a stable low-dose inhaled steroid plan (and not other controller medicines) during the run-in period
- Breathing test rules: lung function (FEV1) must meet a minimum target, and a breathing response test to rescue medicine must be done
- You (parent/guardian) must be able to attend visits and help with daily inhaler use and an electronic symptom diary
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
This study tests a new way to treat asthma flares in children and teens (ages 6–18) with mild-to-moderate asthma. It aims to see if a quick-relief anti-inflammatory medicine works better than current treatments to prevent severe attacks.
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
This study tests a new combination inhaler (budesonide/albuterol) against another asthma inhaler in adults whose asthma is not well controlled on their current medications. It aims to see if the new inhaler can reduce serious asthma attacks and improve symptoms.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.